Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?

Pharmacogenomics - 1 Jan 2015

Rieck Mariana, Schumacher-Schuh Artur F, Callegari-Jacques Sidia M, Altmann Vivian, Schneider Medeiros Márcio, Rieder Carlos Rm, Hutz Mara H

Abstract excerpt

AIM: Levodopa is first line treatment of Parkinson's disease (PD). However, its use is associated with the presence of motor fluctuations and dyskinesias. In recent years, adenosine A2A receptor (A2AR) is rising as a therapeutic target for PD. The aim of the present study was to investigate whether ADORA2A is associated with levodopa adverse effects. PATIENTS & METHODS: Two hundred and eight PD patients on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Genetic Association Studies

Share to Levodopa

Share to Parkinson Disease

Share to Polymorphism, Single Nucleotide

Share to Receptor, Adenosine A2A

Source

Identifiers

PMID: 25872644
DOI: 10.2217/pgs.15.23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?PMID 25872644Read ↗

DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.Semantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's diseaseSemantic proximity Read ↗

Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.Semantic proximity Read ↗

Spinocerebellar ataxia type 2 presenting as familial levodopa‐responsive parkinsonismSemantic proximity Read ↗

Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.Semantic proximity Read ↗

Analysis of ADORA2A rs5760423 and CYP1A2 rs762551 Genetic Variants in Patients with Alzheimer's Disease.Semantic proximity Read ↗

The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population.Semantic proximity Read ↗

The Role of Adenosine Tone and Adenosine Receptors in Huntington's DiseaseSemantic proximity Read ↗

CYP1A2 rs762551 and ADORA2A rs5760423 Polymorphisms in Patients with Blepharospasm.Semantic proximity Read ↗

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.